We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cardiovascular outcomes
MedXY News
EnglishTag

cardiovascular outcomes

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial
Cardiologycardiovascular outcomesmyocardial infarction

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

By MedXY|Oct 7, 2025

A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction s

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
Clinical Updatescardiovascular outcomes
influenza vaccine

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY|Oct 6, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence
Clinical Updatescardiovascular outcomesmaintenance dialysis

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

By MedXY|Oct 5, 2025

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone’s efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing futur

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis
Nephrologycardiovascular outcomeshaemodialysis

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis

By MedXY|Oct 5, 2025

The ALCHEMIST trial reveals spironolactone does not improve cardiovascular outcomes in high-risk chronic haemodialysis patients, aligning with a meta-analysis that challenges the benefit of mineralocorticoid receptor antagonists in this pop

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial
Cardiologycardiovascular outcomesEvolocumab

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY|Oct 4, 2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
Cardiologycardiovascular outcomesOral Semaglutide

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY|Oct 3, 2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial
Cardiologycardiovascular outcomeschronic kidney disease

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY|Oct 3, 2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans
Cardiologyaccess to carecardiovascular outcomes

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

By MedXY|Oct 1, 2025

The MISSION Act reduced travel times to cardiac procedures for veterans distant from VA centers but was linked to higher short-term adverse cardiovascular events for PCI and CABG, highlighting complex trade-offs in access and care quality.

Prev
3 / 3
123
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities